Publication: Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
Loading...
Identifiers
Date
2021-07-16
Authors
Maerevoet, Marie
Zijlstra, Josee M
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J S P
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van Den Neste, Eric
Hill, Brian
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of
Description
MeSH Terms
Age Factors
Aged
Humans
Hydrazines
Lymphoma, Large B-Cell, Diffuse
Neoplasm Recurrence, Local
Survival Analysis
Treatment Outcome
Triazoles
Aged
Humans
Hydrazines
Lymphoma, Large B-Cell, Diffuse
Neoplasm Recurrence, Local
Survival Analysis
Treatment Outcome
Triazoles
DeCS Terms
CIE Terms
Keywords
DLBCL, Exportin-1, SINE compounds, Selinexor